Symptom clusters and their predictors in patients with lung cancer and treated with programmed cell death protein 1 immunotherapy

• DOI: 10.1016/j.apjon.2022.100103
• Publication Date: 2022-06-10T17:50:06Z
• Authors: Guolong Zhang; Huiwen Weng; Yinghong Li; Pingdong Li; Yucui Gong; Jieya Chen; Lin Wei; Linghui Zeng; Yingchun Zeng; Andy SK. Cheng
• Keywords: Stepwise regression; Cross-sectional study

The aims of this study were to examine the symptom severity and interference among patients with lung cancer treated PD-1 immunotherapy, explore whether those symptoms clustered together, identify factors associated clusters.A cross-sectional was conducted. Data collected by demographic clinical characteristic questionnaires M.D. Anderson Symptom Inventory Lung Cancer Module. clusters identified using exploratory factor analysis, stepwise linear regression applied analyze affecting total 148 immunotherapy participated in study. overall burdens these mainly at a mild level. patient general cluster, treatment-related pulmonary gastrointestinal neural cluster. patients' Karnofsky performance status (KPS) score (β ​= ​-2.758, P ​< ​0.001) having history chemotherapy ​4.384, significant predictors Their KPS scores ​-1.202, ​-1.957, monthly income ​-0.316, ​0.030) ​-0.357, ​0.045) Having ​1.868, predictor cluster.The level appeared be clustered. In addition, because that comprise cluster are interrelated, diagnosis management each should not performed isolation, either simultaneously or an orderly manner.